摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3,4,5,6-tetrahydroazepino[4,3-b]indol-1(2H)-one | 14482-89-4

中文名称
——
中文别名
——
英文名称
3,4,5,6-tetrahydroazepino[4,3-b]indol-1(2H)-one
英文别名
2,3,4,5-tetrahydroazepino[4,3-b]indol-1(6H)-one;1,2,3,4,5,6-Hexahydroazepino[4,3-b]indol-1-one;3,4,5,6-tetrahydro-2H-azepino[4,3-b]indol-1-one
3,4,5,6-tetrahydroazepino[4,3-b]indol-1(2H)-one化学式
CAS
14482-89-4
化学式
C12H12N2O
mdl
MFCD24390475
分子量
200.24
InChiKey
UMMKKSLCUIYBIJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    210 °C
  • 沸点:
    524.7±29.0 °C(Predicted)
  • 密度:
    1.259±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.8
  • 重原子数:
    15
  • 可旋转键数:
    0
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.25
  • 拓扑面积:
    44.9
  • 氢给体数:
    2
  • 氢受体数:
    1

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Molecular structure and reactivity of the 1,2-dihydrocarbazol-4(3H)-one: X-ray crystal structure of N-methyl and N-(p-methylbenzenesulfonyl) derivatives
    作者:José Gonzalo Rodríguez、Celestina del Valle、Carmen Esteban-Calderón、Martín Martinez-Ripoll
    DOI:10.1007/bf01665179
    日期:1995.5
    Synthesis and reactivity analysis of the 1,2-dihydrocarbazol-4(3H)-one, and the N-methyl, N-tosyl and 2,2-dimethyl derivatives have been carried out. Molecular structures of the N-methyl and N-tosyl derivatives have been analyzed by X-ray diffraction. Crystals of the N-methyl derivative are monoclinic, space group P21/c,a=8.868(1),b=16.652(1),c=7.5440(4) Å, β=113.657(3). Crystals of the N-tosyl derivative
    已经进行了 1,2-dihydrocarbazol-4(3H)-one 和 N-甲基、N-甲苯磺酰基和 2,2-二甲基衍生物的合成和反应性分析。N-甲基和N-甲苯磺酰基衍生物的分子结构已通过X-射线衍射分析。N-甲基衍生物的晶体为单斜晶系,空间群P21/c,a=8.868(1),b=16.652(1),c=7.5440(4) Å, β=113.657(3)。N-甲苯磺酰基衍生物的晶体为单斜晶系,P21/c,a=12.0016(3),b=8.9178(2),c=16.0485(4) Å,β=104.372(2)。在这两种情况下,从羰基到氮原子的扩展共轭和常见环己烯酮片段的包膜构象都很明显。肟化和贝克曼重排,以及羰基的醚化。
  • Enantioselective synthesis of <i>cis</i>-hexahydro-<i>γ</i>-carboline derivatives <i>via</i> Ir-catalyzed asymmetric hydrogenation
    作者:Long-Sheng Zheng、Congcong Yin、Fangyuan Wang、Gen-Qiang Chen、Xumu Zhang
    DOI:10.1039/d1cc06888a
    日期:——
    A novel synthetic route was developed for the construction of a chiral cis-hexahydro-γ-carboline derivative through Ir/ZhaoPhos-catalyzed asymmetric hydrogenation of corresponding tetrahydro-γ-carboline with high yields (up to 99% yield), excellent diastereoselectivities (up to >99 : 1 dr) and enantioselectivities (up to 99% ee), and high substrate-to-catalyst ratios (up to 5000).
    开发了一种新的合成路线,用于通过 Ir/ZhaoPhos 催化相应四氢-γ-咔啉的不对称氢化构建手性顺式-六氢-γ-咔啉衍生物,收率高(收率高达 99%),具有优异的非对映选择性(高达至 >99 : 1 dr)和对映选择性(高达 99% ee),以及高底物催化剂比(高达 5000)。
  • New azepino[4,3-b]indole derivatives as nanomolar selective inhibitors of human butyrylcholinesterase showing protective effects against NMDA-induced neurotoxicity
    作者:Modesto de Candia、Giorgia Zaetta、Nunzio Denora、Domenico Tricarico、Maria Majellaro、Saverio Cellamare、Cosimo D. Altomare
    DOI:10.1016/j.ejmech.2016.09.037
    日期:2017.1
    Several 6-substituted 3,4,5,6-tetrahydroazepino[4,3-b]indol-1(2H)-one (THAI) derivatives were synthesized and evaluated for their activity as cholinesterase (ChE) inhibitors. The most potent inhibitors were identified among 6-(2-phenylethyl)-THAI derivatives, and in particular compounds 12b and 12d proved to be very active against human BChE (IC50 = 13 and 1.8 nM, respectively), with 1000-fold selectivity
    合成了几种6-取代的3,4,5,6-四氢氮杂环庚烷[4,3- b ]吲哚-1(2 H)-one(THAI)衍生物,并评估了其作为胆碱酯酶(ChE)抑制剂的活性。在6-(2-苯乙基)-THAI衍生物中鉴定出最有效的抑制剂,特别是化合物12b和12d被证明对人类BChE具有非常高的活性(分别为IC 50  = 13和1.8 nM),具有1000倍的选择性超过AChE。构效关系突出了关键特征(例如环融合[4,3- b],内酰胺CONH功能的完整性)和6-(2-苯乙基)基团的有利物理化学性质(即,苯基取代基的最佳位置,大小和亲脂性)。还评估了许多化合物对NMDA诱导的SH-SY5Y神经元细胞损伤的作用。用12b处理可提高用250μMNMDA预处理的SH-SY5Y细胞的细胞活力, 在0.5至5μM的浓度下具有显着影响(P <0.05)。这些发现表明,THAI可以用作开发用于治疗阿尔茨海默氏型神经变性综合征的新药物的支架。
  • Investigating 1,2,3,4,5,6-hexahydroazepino[4,3-b]indole as scaffold of butyrylcholinesterase-selective inhibitors with additional neuroprotective activities for Alzheimer's disease
    作者:Rosa Purgatorio、Modesto de Candia、Marco Catto、Antonio Carrieri、Leonardo Pisani、Annalisa De Palma、Maddalena Toma、Olga A. Ivanova、Leonid G. Voskressensky、Cosimo D. Altomare
    DOI:10.1016/j.ejmech.2019.05.062
    日期:2019.9
    Due to the role of butyrylcholinesterase (BChE) in acetylcholine hydrolysis in the late stages of the Alzheimer's disease (AD), inhibitors of butyrylcholinesterase (BChE) have been recently envisaged, besides acetylcholinesterase (AChE) inhibitors, as candidates for treating mild-to-moderate AD. Herein, synthesis and AChE/BChE inhibition activity of some twenty derivatives of 1,2,3,4,5,6-hexahydroazepino[4
    由于阿尔茨海默氏病(AD)晚期丁酰胆碱酯酶(BChE)在乙酰胆碱水解中的作用,除乙酰胆碱酯酶(AChE)抑制剂外,最近还设想了丁酰胆碱酯酶(BChE)抑制剂可作为治疗轻度至中度肝炎的候选药物。适度的广告。在此,报道了1,2,3,4,5,6-六氢az庚啶[4,3- b ]吲哚(HHAI)的约二十种衍生物的合成和AChE / BChE抑制活性。大多数新合成的HHAI衍生物都可以在微摩尔范围内用IC 50抑制两种ChE异构体,并且对BChE具有结构依赖性的选择性。显然,分子体积和亲脂性确实增加了对BChE的选择性,实际上增加了N 2-(4-苯基丁基)HHAI衍生物的选择性。充当混合型抑制剂的15d对马血清和人BChE产生了最有效的(IC 50 0.17μM)和选择性的(> 100倍)抑制剂。此外,15d抑制神经毒性淀粉样β(Aβ)肽的体外自我诱导聚集,并在神经母细胞瘤SH-SY5Y细胞系中显示出
  • Evaluation of Water‐Soluble Mannich Base Prodrugs of 2,3,4,5‐Tetrahydroazepino[4,3‐ <i>b</i> ]indol‐1(6 <i>H</i> )‐one as Multitarget‐Directed Agents for Alzheimer's Disease
    作者:Rosa Purgatorio、Modesto Candia、Marco Catto、Mariagrazia Rullo、Leonardo Pisani、Nunzio Denora、Antonio Carrieri、Alisa A. Nevskaya、Leonid G. Voskressensky、Cosimo D. Altomare
    DOI:10.1002/cmdc.202000583
    日期:2021.2.4
    Different Mannich base derivatives have been studied with the aim of addressing the poor aqueous solubility of the recently disclosed 6‐phenethyl‐2,3,4,5‐tetrahydroazepino[4,3‐b]indol‐1(6H)‐one (1), a human butyrylcholinesterase inhibitor (hBChE, IC5013 nM) and protective agent in NMDA‐induced neurotoxicity, in in vivo assays. The N‐(4‐methylpiperazin‐1‐yl)methyl derivative 2 c showed a 50‐fold increase
    已经研究了不同的曼尼希碱衍生物,目的是解决最近公开的 6-苯乙基-2,3,4,5-四氢氮杂[4,3 - b ]indol-1(6 H )-one ( 1 ),一种人丁酰胆碱酯酶抑制剂 (hBChE,IC 50 13 nM) 和 NMDA 诱导的神经毒性保护剂,在体内试验中。所述ñ - (4-甲基哌嗪-1-基)甲基衍生物2 C显示在pH 7.4的缓冲溶液中的溶解度为50倍的增加,在血清中高稳定性和(半衰期> 24小时)和快速(<3分钟)在酸性 pH 值下转化为1。虽然不如1 , 2 c活跃保留了中度 hBChE 抑制(IC 50 = 3.35 μM),并在 0.1 μM 时对 NMDA 诱导的神经毒性具有显着的保护作用。此外,2 c导致比1 更弱的血清白蛋白结合物,可以通过血脑屏障,对 HepG2 细胞的细胞毒性可以忽略不计。这些结果表明,2 C可能是一个水溶性前药的候选1用于口服给药或缓释注射衍生物在体内阿尔茨海默氏病的模型。
查看更多

同类化合物

环戊二烯并[4,5]氮杂卓并[2,1,7-cd]吡咯里嗪 吡咯并[1,2-a]氮杂-5-酮 六氢-1H-吡咯并[1,2-A]氮杂卓-5(6H)-酮 N,N-二甲基-3-(3-甲基-1,2,4,5-四氢氮杂卓并[4,5-b]吲哚-6-基)丙-1-胺 9-氟-1,2,3,4,5,6-六氢氮杂卓并[4,5-b]吲哚 7,8-二氢-5H-吡咯并[1,2-A]氮杂环庚烷-9(6H)-酮 6-叔-丁基3A-乙基八氢吡咯并[2,3-D]氮杂卓-3A,6(2H)-二甲酸基酯 6,7-二氢吡咯并[2,3-c]氮杂卓-4,8(1H,5H)-二酮 5H-吡咯并[1,2-a]氮杂卓-7-醇 5,9:7,11-二亚甲基-5H-吡咯并[1,2-a]吖壬英-3-羧酸,6,7,8,9,10,11-六氢-,甲基酯 4-(2-氨基-1H-咪唑-5-基)-2,3-二溴-6,7-二氢吡咯并[2,3-c]氮杂卓-8(1H)-酮 4-(2-氨基-1H-咪唑-4-基)-2,3-二溴-4,5,6,7-四氢吡咯并[2,3-c]氮杂卓-8(1H)-酮 4-(2-氨基-1,5-二氢-5-氧代-4H-咪唑-4-亚基)-4,5,6,7-四氢-吡咯并[2,3-c]氮杂卓-8(1H)-酮 3-苄基-1,2,3,4,5,6-六氢氮杂卓并[4,5-b]吲哚 3-(3,9-二甲基-1,2,4,5-四氢氮杂卓并[4,5-b]吲哚-6-基)-N,N-二甲基丙烷-1-胺 2H,3H-氧杂环丁烷并[3,2-d]吡咯并[1,2-a]氮杂卓 2-溴-6,7-二氢-1h,5h-吡咯并[2,3-c]氮杂烷-4,8-二酮 2,5-已炔二醇 2,3,4,5-四氢-N,N-二甲基-2-(3,4,5-三甲氧基苯甲酰基)-氮杂卓并(3,4-b)吲哚-10(1H)-丙胺 11-氧杂-3,10-二氮杂三环[7.2.1.03,7]十二碳-1,4,6,9-四烯 1,4,5,6,7,8-六氢吡咯并[3,2-b]氮杂卓 1,2,3,4,5,6-六氢氮杂环庚烷[4,3-B]吲哚盐酸盐 1,2,3,4,5,6-六氢-9-甲基氮杂卓并[4,5-b]吲哚 1,2,3,4,5,6-六氢-6-甲基氮杂革[4,5-b]吲哚盐酸盐 1,2,3,4,5,6-六氢-3-甲基氮杂卓并[4,5-b]吲哚 (1R*,2E,11S*)-2-(cyclohexylmethylene)-1-(phenylsilyl)methyloctahydropyrrolo[1,2-a]azepine (R)-2-(6,7,8,9-tetrahydro-5H-pyrrolo[1,2-a]azepin-9-yl)-acetaldehyde curvulamine (3aR,8aS)-tert-butyl octahydropyrrolo[3,4-d]azepine-2(1H)-carboxylate hydrochloride tert-butyl 6-(2-amino-2-oxoethyl)-1,4,5,6-tetrahydroazepino[4,5-b]indole-3(2H)-carboxylate 3-benzoyl-10-bromo-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole 3-(tert-butyloxycarbonyl)-10-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole 1,2,3,4,5,6-hexahydro-3-dimethylaminoethyl-5-hydroxymethylazepino[4,5-b]indole 1,2,3,4,5,6-hexahydro-3-dimethylaminoethyl-5-hydroxymethyl-6-methylazepino[4,5-b]indole (Z)-2,3,9,9a-tetrahydro-6,6-dimethyl-9-methylene-8-vinyl-1H-pyrrolo[1,2-a]azepin-5(6H)-one 2,3,4,5,6,7-hexahydro-1H-3a,8,13,13b-tetraazabenzo[b]cyclopenta[1,2,3-jk]fluorene 2,3,4,5,6,7-hexahydro-1H-3a,8,11,11b-tetraazacyclohepta[1,2,3-jk]fluorene 1-Benzyloxy-2-methoxy-7,8,9,10-tetrahydro-6H-azepino<1,2-a>indole-11-carbaldehyde 3-benzoyl-10-(2-propoxyphenyl)-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole 2-phenyl-2,4,5,6-tetrahydro-1H-6-azabenzo[a]cyclohepta[cd]azulen-1-one 2-carbetoxy-3-(N,N-dimethyl)aminomethyleneamino-8-oxo-8H-4,5,6,7-tetrahydropyrrolo<2,3-c>azepine 3-benzoyl-10-[2-(trifluoromethyl)phenyl]-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole 3-benzoyl-10-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole 6-[2-(4-fluorophenyl)ethyl]-3,4,5,6-tetrahydroazepino[4,3-b]indol-1(2H)-one 5-(2-hydroxy-3-morpholin-4-yl-propyl)-3-methyl-4-oxo-1,4,5,6,7,8-hexahydro-pyrrolo[3,2-c]azepine-2-carbaldehyde 6-(2-phenylethyl)-3,4,5,6-tetrahydroazepino[4,3-b]indol-1(2H)-one 11-(tert-butyldimethylsilyloxy)-1-trimethylsilyl-3a,4,11,12-tetrahydro-3H-cyclopenta[5,6]azepine[1,2-a]indole-2-one tert-butyl 8,9-dichloro-6-[2-(2,3-dimethylanilino)-2-oxoethyl]-1,4,5,6-tetrahydroazepino[4,5-b]indole-3(2H)-carboxylate tert-butyl 9,10-dichloro-6-[2-(2,3-dimethylanilino)-2-oxoethyl]-1,4,5,6-tetrahydroazepino[4,5-b]indole-3(2H)-carboxylate tert-butyl (1R,4S)-1-(benzylcarbamoyl)-3-oxo-2-((S)-1-phenylethyl)-1,2,3,4,5,10-hexahydroazepino[3,4-b]indol-4-ylcarbamate